Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review.

Cancers (Basel) · 2022 · PMC9367458 · PMID 35954437

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Several studies showed a similar trend but did not reach statistical significance, primarily due to low sample sizes during subgroup analyses performed to exclude confounding patient factors.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.